Friday, March 27, 2026 6:12:17 PM
Don’t forget about this-
It doesn’t hurt that our VP US Medical Affairs David Gould, is a personal acquaintance of Dr Makery.
I sure that they have had a discussion.
Jesse Silveira (Mayomobile) had an interview with some members of Anavex management. David Gould, US medical affairs, and Henk Nab, VP Medical affairs.
"I asked about the new commissioners voucher program... if the company intended to pursue that. They all confirmed that "we are interested"
Obviously take for that what you will. I affirmed that the company meets the goals of the new voucher, and Nell assured me she sent all the details to Dr. Missling some time ago. She also stated that Dr. Missling met with Dr. Marty Makary (FDA Head) somewhat recently (NFI).
David chimed in that he has Dr. Makary's phone number and knows him personally - an interesting comment from Anavex's new U.S.
Medical Affairs staffer."
" the direction of the "new" FDA is still being established and the company needs to speak with the
FDA to see their directionality and any milestones the company may need to meet in order to file/get approved in the United States. Again, it was brought up that Dr. Missling recently spoke with Dr. Makary and that David knows Makary and they will try to leverage these relationships to understand what they (Anavex) need to do. Filing with the FDA and which method they will accomplish this is still in conversation.
It doesn’t hurt that our VP US Medical Affairs David Gould, is a personal acquaintance of Dr Makery.
I sure that they have had a discussion.
Jesse Silveira (Mayomobile) had an interview with some members of Anavex management. David Gould, US medical affairs, and Henk Nab, VP Medical affairs.
"I asked about the new commissioners voucher program... if the company intended to pursue that. They all confirmed that "we are interested"
Obviously take for that what you will. I affirmed that the company meets the goals of the new voucher, and Nell assured me she sent all the details to Dr. Missling some time ago. She also stated that Dr. Missling met with Dr. Marty Makary (FDA Head) somewhat recently (NFI).
David chimed in that he has Dr. Makary's phone number and knows him personally - an interesting comment from Anavex's new U.S.
Medical Affairs staffer."
" the direction of the "new" FDA is still being established and the company needs to speak with the
FDA to see their directionality and any milestones the company may need to meet in order to file/get approved in the United States. Again, it was brought up that Dr. Missling recently spoke with Dr. Makary and that David knows Makary and they will try to leverage these relationships to understand what they (Anavex) need to do. Filing with the FDA and which method they will accomplish this is still in conversation.
Recent AVXL News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2026 12:15:26 PM
- Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification • GlobeNewswire Inc. • 05/22/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 08:15:25 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 08:15:30 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/11/2026 08:30:22 PM
- CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in Focus • IH Market News • 05/06/2026 02:52:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:04:59 AM
- Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 11:18:47 PM
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
